Bio Protocol vs COTI — how do they compare? Bio Protocol trades at Rp439.3 (market cap Rp996,68M, Rp165,43M 24h volume), while COTI trades at Rp199.17 (market cap Rp590,87M, Rp1,18T 24h volume). The key difference: Bio Protocol is the larger of the two by market cap, and Bio Protocol's circulating supply is 2,3B / 3,3B BIO (69%) versus 3B / 4,9B COTI (61%) for COTI. Which is the better fit depends on your goals — on Pluang, investors hold Bio Protocol for 18 Days and COTI for 120 Days on average.
| BIO | COTI | |
|---|---|---|
Market Cap | Rp996,68M | Rp590,87M |
Volume (24h) | Rp165,43M | Rp1,18T |
Circulating Supply | 2,3B / 3,3B BIO (69%) | 3B / 4,9B COTI (61%) |
Typical Hold Time | 18 Days | 120 Days |
Signals from Pluang's Aura AI — not financial advice
Bio Protocol (BIO) trades at Rp438.8 with a market cap of Rp996.68M, showing neutral technical signals overall. The token is currently testing the pivot point at Rp440, with immediate support at Rp430 and resistance at Rp454. With 69% of max supply in circulation and an average hold time of 18 days, the token exhibits moderate liquidity. Recent technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains neutral with key opportunities in potential breakout above Rp454 resistance. Major risks include low market cap vulnerability to volatility and limited fundamental developments. Investors should monitor trading volume patterns and broader crypto market sentiment for directional cues.
COTI is trading at Rp199.43 with a bearish technical signal, currently testing support near S1 (Rp176) with oversold RSI hints. The market cap is Rp590.52M with 61% of supply circulating. No major protocol updates were noted recently.
Overall outlook remains cautious due to bearish momentum and limited fundamental catalysts. Key opportunities include potential rebound from oversold levels, while risks involve low liquidity and high volatility typical of small-cap crypto assets.
What Pluang investors did over the last 30 days
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →COTI markets itself as the first enterprise-grade fintech platform that empowers organizations to build their own payment solutions as well as digitize any currency to save time as well as money. It is one of the world’s first blockchain protocols that is optimized for decentralized payments and designed for use by merchants, governments, payment DApps, and stablecoin issuers.
Read more on COTI →